Treatment registry sits at the center of this dementia and brain health question.
Alzheimer’s treatment registries are transforming how we understand which therapies actually work in real patients—not just in controlled clinical trials. Rather than relying solely on data from carefully selected study populations, registries like ALZ-NET and InRAD track thousands of individuals receiving Alzheimer’s medications in everyday clinical practice, revealing what happens when a lecanemab infusion is given to a 70-year-old with comorbidities, or when a patient misses follow-up appointments. The first real-world data from ALZ-NET presented at CTAD 2025 showed something reassuring: when people received treatment in early disease stages (mild cognitive impairment and mild dementia), their cognitive and functional status remained stable or improved during the first year—mirroring what clinical trials had predicted, but now confirmed across diverse patient populations in different treatment centers.
This article explains how these registries work, what the emerging data shows about treatment outcomes and safety, and why real-world evidence matters for patient decision-making. Treatment registries capture the messiness of actual clinical care—patients with multiple health conditions, varying medication adherence, different ages and backgrounds—alongside structured safety monitoring. A real-world study of 178 lecanemab-treated patients from Eisai found that 83.6% either remained at the same clinical stage or improved, with 76.9% remaining stable and 6.7% improving from mild dementia back to mild cognitive impairment. This is valuable context for someone considering treatment: you’re not looking at artificial best-case data, but rather what realistic outcomes look like in practice.
Table of Contents
- What Are Alzheimer’s Treatment Registries and Why Do They Matter?
- Real-World Safety Data: What the Numbers Tell Us About Adverse Events
- What Real-World Outcomes Look Like for Early Treatment
- How Patient Selection and Willingness Affect Registry Data
- Monitoring and Data Quality in Global Registries
- Comparing Registry Findings to Clinical Trial Results
- Future Direction and Upcoming Real-World Data
- Conclusion
- Frequently Asked Questions
What Are Alzheimer’s Treatment Registries and Why Do They Matter?
Registries differ fundamentally from traditional clinical trials. In a clinical trial, researchers control who participates, how often patients are monitored, and how treatment is delivered. In a registry, healthcare providers enroll their own patients and contribute data on an ongoing basis, capturing the natural flow of clinical practice. InRAD (International Registry for Alzheimer’s Disease and Other Dementias) exemplifies this approach—it’s a voluntary network where healthcare providers across multiple countries contribute clinical and safety data on their Alzheimer’s patients in real-world settings.
This means a neurologist in Denmark and a memory care specialist in the United States are both feeding information into the same dataset, revealing whether treatment outcomes and side effects differ based on healthcare system, patient population, or local practice patterns. The critical advantage is that registries answer the question clinical trials can’t always address: “What actually happens when we treat this medicine in my community?” A patient newly diagnosed at age 72 with early Alzheimer’s and Type 2 diabetes wants to know whether lecanemab works for people like them—not for the carefully selected 55-75 year-old trial participants without significant comorbidities. Registries provide that evidence. The ALZ-NET data showed that early treatment participation trends closely match clinical trial demographics, suggesting that the patients being treated in real practice are indeed similar to trial populations, which increases confidence that trial outcomes translate to broader use.
Real-World Safety Data: What the Numbers Tell Us About Adverse Events
One concern about newer Alzheimer’s treatments like lecanemab is amyloid-related imaging abnormalities (ARIA)—brain microhemorrhages or microinfarcts that appear on MRI but often cause no symptoms. The clinical trial data showed these occurred in roughly 10-15% of treated patients, but registries are now capturing what happens outside the controlled trial setting. Among lecanemab-treated patients tracked by Eisai, 12.9% experienced any amyloid-related imaging abnormality, with 7.9% showing ARIA-E (microhemorrhages) and 6.2% showing ARIA-H (microinfarcts). The important caveat: most were asymptomatic, meaning the patient felt no cognitive decline or physical symptoms despite the imaging findings. However, the real-world data has exposed potential vulnerabilities.
ARIA rates in trials assumed regular MRI monitoring every 18 months and careful assessment of risk factors like cognitive impairment and apolipoprotein E4 (APOE4) status. In actual practice, not all treatment centers have equal access to MRI capability or neuroradiologists to interpret subtle changes. A patient in a rural area receiving lecanemab may have less frequent imaging than someone at a major academic center, which could delay detection of asymptomatic ARIA. This is why registry data matters—it’s revealing these real-world gaps in surveillance. The Wisconsin Registry for Alzheimer’s Prevention, which has maintained an 81% retention rate over nine years with over 1,270 active participants (mean age 64 with extensive follow-up), provides the longitudinal perspective necessary to track whether asymptomatic ARIA remains truly silent or whether some patients experience delayed cognitive effects.
What Real-World Outcomes Look Like for Early Treatment
The ALZ-NET registry’s first data readout confirmed that most individuals receiving Alzheimer’s treatment are being treated in early disease stages—mild cognitive impairment and early mild dementia—rather than at later stages. This aligns with how the medications were tested and approved. During the first year of therapy in this real-world population, the registry documented stable cognition and function, with ARIA rates consistent with clinical trial expectations. Translated to practical terms: a 68-year-old woman diagnosed with mild cognitive impairment who starts lecanemab can reasonably expect her cognition to hold steady over the next year rather than decline, assuming she tolerated the medication and attended infusions. One example illustrates why this matters.
The Eisai real-world data showed 76.9% of 178 lecanemab-treated patients remained at the same clinical stage after treatment. If that patient was at the mild dementia stage when starting lecanemab, remaining stable means she hasn’t progressed to moderate dementia. Over the natural course of untreated Alzheimer’s, a person at that stage might expect to decline noticeably within a year. The 6.7% who improved from mild dementia to mild cognitive impairment represent a smaller but meaningful subset who actually reversed some cognitive decline—rare in Alzheimer’s, and not guaranteed by any medication, but documented in real practice. This is why registries reveal nuances that clinical trials can miss: trials show aggregate efficacy, but registries show the distribution of outcomes (some stable, some improving, some still declining despite treatment) in realistic populations.
How Patient Selection and Willingness Affect Registry Data
A crucial factor shaping registry findings is who chooses to participate in treatment. The Alzheimer’s Association 2025 report found that 83% of individuals diagnosed with Alzheimer’s disease were willing to participate in treatment trials, and notably, 48% cited the ability to participate in clinical trials as a reason they wanted Alzheimer’s testing in the first place. This reveals motivated, engaged patients—those who understand their diagnosis and actively seek treatment. In registries, the patients contributing data are similarly self-selected: they’ve sought out specialists, agreed to ongoing monitoring, and committed to regular infusions. This creates a potential limitation in interpreting registry data.
The outcomes reported may reflect a slightly healthier or more engaged population than the broader community of Alzheimer’s-diagnosed individuals. Not every diagnosed person pursues treatment; some decline it due to cost, burden, or clinical judgment that they’re too frail. Registry data therefore shows outcomes in people willing and able to undergo treatment, not a representative sample of all diagnosed Alzheimer’s patients. A registry finding that “76.9% remained stable” doesn’t tell you what would happen in patients who declined treatment or were deemed unsuitable—a different population entirely. When evaluating whether treatment is right for you or a family member, it’s important to recognize that registries capture outcomes in self-selected, engaged, treatment-willing populations.
Monitoring and Data Quality in Global Registries
Registries span international healthcare systems with different infrastructure, data standards, and medical practice patterns. InRAD operates across multiple countries, which enriches the dataset—it reveals whether lecanemab works similarly in a German hospital as in a clinic in Spain. However, it also introduces variability in how data is collected, how frequently patients are monitored, and how adverse events are detected and reported. A healthcare system with robust MRI access will detect more asymptomatic ARIA; a system with less frequent imaging may miss it entirely.
The Wisconsin Registry for Alzheimer’s Prevention addressed this by implementing structured data collection: semiannual data snapshots with fixed May and November lock dates ensure consistent intervals and comparable data points across all 1,270+ participants. This systematic approach has maintained an 81% retention rate over nine years—significantly higher than many clinical trials. However, even well-designed registries face the challenge of missing data: patients move, change providers, or decline further participation. The retained 81% at Wisconsin likely differs from those who dropped out, potentially skewing outcomes toward more stable or satisfied participants. When reading registry conclusions, it’s worth asking: how complete was follow-up, and did losses to follow-up create bias?.
Comparing Registry Findings to Clinical Trial Results
The clinical trials for lecanemab (Clarity AD, Clarity II) showed that treated patients declined more slowly than placebo—a 35% slowing of cognitive decline over 18 months in early-stage patients. Real-world registry data doesn’t measure decline rate the same way; instead, it tracks whether patients remain at the same stage, improve, or progress to the next stage. The ALZ-NET finding that “most individuals showed stable cognition and function during the first year” aligns directionally with trial results but isn’t directly comparable. One treats decline rate as a continuous measure; the other uses categorical stability.
This difference is worth understanding because marketing or media coverage sometimes conflates the two, creating confusion. A patient or caregiver reading that a drug “slowed decline by 35%” in trials but “keeps cognition stable” in real-world registries may assume these are different findings when they’re actually measuring the same biological effect in different ways. Real-world registries provide the practical answer (“Will Mom stay at the same level?”), while trials provide the statistical answer (“How much slower will decline be?”). Both are valuable, and together they offer a more complete picture than either alone.
Future Direction and Upcoming Real-World Data
Eisai has scheduled presentations of the latest long-term real-world treatment data on lecanemab for the AD/PD™ 2026 Conference (March 17-21 in Copenhagen, Denmark). This is significant because current registry data spans roughly one year of follow-up; the AD/PD 2026 presentations will extend that to 18-24 months, revealing whether stability in year one continues or whether decline resumes.
It will also provide time for rarer adverse events or delayed ARIA progression to emerge. This forward-looking data matters for patients considering treatment today, because it will answer the question, “What happens after the first year?” International registries like InRAD and ALZ-NET are also expanding to include newer Alzheimer’s treatments beyond lecanemab—such as donanemab, which is entering real-world use. As these medications accumulate registry data, comparative evidence will emerge: which treatment works better for which patient population? Do certain risk factors (like APOE4 status or presence of hypertension) predict better or worse outcomes with specific drugs? Real-world data will eventually answer these nuanced questions that clinical trials, by design, cannot.
Conclusion
Alzheimer’s treatment registries are shifting the evidence base for dementia care from controlled research settings to the real world, revealing that the outcomes and safety profiles observed in clinical trials largely hold up when treatments are delivered in diverse patient populations across different healthcare systems. The early data from ALZ-NET, Eisai’s real-world lecanemab studies, and international registries like InRAD show that patients treated in early disease stages experience cognitive and functional stability during the first year, with adverse event rates consistent with trials—reassuring information for individuals considering treatment. However, registries also illuminate important caveats: they capture outcomes in engaged, treatment-willing populations; they depend on consistent monitoring and data infrastructure; and they’re still early in providing long-term outcomes beyond one to two years.
If you or a loved one has been diagnosed with early Alzheimer’s disease or mild cognitive impairment and is considering anti-amyloid treatment, real-world registry data provides complementary evidence to clinical trial results. Discussing your specific risk factors, preferences, and monitoring plans with a neurologist or memory care specialist remains essential, as does understanding that stability—while a meaningful difference from expected decline—is not a cure. As registries accumulate additional follow-up data and newer treatments enter the real-world pipeline, the evidence base will continue to evolve, offering increasingly granular guidance about which treatments benefit which patients.
Frequently Asked Questions
Do the adverse events reported in registries reflect what will happen to me personally?
Registry data describes what happened in a population—in the Eisai real-world study, 12.9% experienced any ARIA. This means roughly 1 in 8 treated patients had imaging findings, though most were asymptomatic. Your individual risk depends on factors like age, APOE4 status, and comorbidities. A specialist can discuss your personal risk based on this population data and your health profile.
Why do registry outcomes differ from clinical trial results?
They don’t differ fundamentally—they measure the same underlying effect differently. Trials quantify “rate of decline” (35% slowing), while registries track “stage stability” (patient stays at same level). Real-world registries are also conducted in broader, less carefully selected populations, which can introduce more variability in outcomes.
Are the patients in registries representative of all Alzheimer’s patients?
No. Registries capture people who sought diagnosis, were deemed suitable for treatment, and agreed to ongoing monitoring. People who declined treatment, couldn’t access it, or were deemed too frail are not represented. Registry outcomes therefore describe treated, engaged populations, not all diagnosed individuals.
When will we have longer-term registry data?
The AD/PD 2026 Conference (March 2026) will present extended real-world data extending to 18-24 months. Registries with longer follow-up—like Wisconsin’s, which has 9 years of data—typically show accumulated effects only for observational monitoring rather than specific treatment interventions since most drugs are newer to real-world use.
Should I rely on registry data or clinical trials when deciding about treatment?
Both. Clinical trials establish efficacy and safety under ideal conditions; registries confirm those findings in real practice and reveal practical considerations like monitoring gaps or outcomes in specific subgroups. Use trials to understand the drug’s evidence base and registries to understand how that translates to your actual healthcare setting.
How do I know if registry data is reliable?
Look for published data (presented at major conferences like CTAD or AD/PD) from established registries with structured protocols, long retention rates, and transparent reporting of limitations. Registries like Wisconsin (81% retention over 9 years) and ALZ-NET (first data readout at CTAD 2025) demonstrate methodological rigor worth trusting.
You Might Also Like
- Patient Data Shows Strong Adherence to Approved Alzheimer’s Treatment
- Researchers Propose Fundamental Shift in Alzheimer’s Treatment Strategy
- Protein Complex Discovery Opens New Avenue for Alzheimer’s Treatment
For more, see National Institute on Aging.
